Meaning-Centered Psychotherapy in Advanced Cancer - Tabular View

Tracking Information

First Received Date ^ICMJE

August 14, 2003

Last Updated Date

August 16, 2006

Start Date ^ICMJE

May 2002

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00067288 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Meaning-Centered Psychotherapy in Advanced Cancer

Official Title ^ICMJE

Meaning-Centered Psychotherapy in Advanced Cancer

Brief Summary

We have developed an 8-week Meaning-Centered Group Psychotherapy designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose despite the limitations of their cancer illness. This project's overall aim is to explore the feasibility and efficacy of this new and unique psychotherapy intervention for advanced cancer patients in enhancing psychological and spiritual well-being and quality of life by comparing it with a standard supportive group psychotherapy.

Detailed Description

As per Brief Summary

Study Phase

Phase II

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Educational/Counseling/Training, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study

Condition ^ICMJE

Lymphoma, Non-Hodgkin
Neoplasms

Intervention ^ICMJE

Behavioral: Meaning-Centered Group Psychotherapy
Behavioral: Standard Supportive Group Psychotherapy

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

118

Completion Date

March 2006

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

21 years of age or older;
English speaking;
Stage III or IV solid-tumor or Non-Hodgkin's Lymphoma;
Receiving ambulatory care at Memorial Sloan-Kettering Cancer Center in New York City;

Exclusion Criteria:

Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in a group-format intervention;
Presence of cognitive impairment disorder, such as delirium or dementia that is sufficient, in the investigator's opinion, to preclude meaningful participation and/or informed consent;
Karnofsky Performance Rating Scale below 50 or physical limitations or illness severity sufficient to preclude participation in outpatient group psychotherapy.

Gender

Both

Ages

21 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00067288

Responsible Party

Study ID Numbers ^ICMJE

R21 AT001031-01, Breitbart

Study Sponsor ^ICMJE

National Center for Complementary and Alternative Medicine (NCCAM)

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:	William Breitbart, MD	Memorial Sloan-Kettering Cancer Center
Investigator:	Christopher Gibson, PhD	Project Coordinator Memorial Sloan-Kettering Cancer Center

Information Provided By

National Center for Complementary and Alternative Medicine (NCCAM)

Verification Date

August 2006

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP